A detailed history of D. E. Shaw & Co., Inc. transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 771,138 shares of EBS stock, worth $6.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
771,138
Holding current value
$6.49 Million
% of portfolio
0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.72 - $14.77 $324,083 - $836,838
-56,658 Reduced 6.84%
771,138 $6.44 Million
Q2 2024

Aug 14, 2024

BUY
$1.86 - $6.98 $764,705 - $2.87 Million
411,132 Added 98.67%
827,796 $5.65 Million
Q1 2024

May 15, 2024

SELL
$1.5 - $3.41 $1.15 Million - $2.63 Million
-769,888 Reduced 64.88%
416,664 $1.05 Million
Q4 2023

Feb 14, 2024

BUY
$1.82 - $3.16 $455,061 - $790,107
250,034 Added 26.7%
1,186,552 $2.85 Million
Q3 2023

Nov 14, 2023

SELL
$3.17 - $7.91 $131,234 - $327,466
-41,399 Reduced 4.23%
936,518 $3.18 Million
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.21 $2.84 Million - $5.1 Million
-385,863 Reduced 28.29%
977,917 $7.19 Million
Q1 2023

May 15, 2023

SELL
$7.79 - $16.29 $2.09 Million - $4.36 Million
-267,838 Reduced 16.42%
1,363,780 $14.1 Million
Q4 2022

Feb 14, 2023

BUY
$11.0 - $21.45 $7.03 Million - $13.7 Million
639,405 Added 64.44%
1,631,618 $19.3 Million
Q3 2022

Nov 14, 2022

SELL
$20.09 - $35.8 $1.48 Million - $2.64 Million
-73,734 Reduced 6.92%
992,213 $20.8 Million
Q2 2022

Aug 15, 2022

SELL
$27.42 - $43.63 $2.68 Million - $4.26 Million
-97,639 Reduced 8.39%
1,065,947 $33.1 Million
Q1 2022

May 16, 2022

BUY
$36.48 - $52.22 $7.96 Million - $11.4 Million
218,248 Added 23.09%
1,163,586 $47.8 Million
Q4 2021

Feb 14, 2022

BUY
$33.11 - $55.01 $29.2 Million - $48.6 Million
882,893 Added 1413.87%
945,338 $41.1 Million
Q3 2021

Nov 15, 2021

BUY
$50.07 - $66.05 $2.65 Million - $3.49 Million
52,852 Added 550.94%
62,445 $3.13 Million
Q2 2021

Aug 16, 2021

BUY
$56.61 - $80.46 $543,059 - $771,852
9,593 New
9,593 $604,000
Q1 2021

May 17, 2021

SELL
$86.23 - $125.19 $1.12 Million - $1.63 Million
-12,991 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$79.17 - $111.47 $1.03 Million - $1.45 Million
12,991 New
12,991 $1.16 Million
Q3 2020

Nov 16, 2020

SELL
$81.91 - $134.94 $651,512 - $1.07 Million
-7,954 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$54.33 - $89.52 $2.05 Million - $3.38 Million
-37,703 Reduced 82.58%
7,954 $629,000
Q1 2020

May 15, 2020

SELL
$49.34 - $68.76 $2.55 Million - $3.55 Million
-51,701 Reduced 53.1%
45,657 $2.64 Million
Q4 2019

Feb 14, 2020

SELL
$51.21 - $59.06 $914,456 - $1.05 Million
-17,857 Reduced 15.5%
97,358 $5.25 Million
Q3 2019

Nov 14, 2019

BUY
$40.6 - $57.2 $3.1 Million - $4.36 Million
76,298 Added 196.05%
115,215 $6.02 Million
Q2 2019

Aug 14, 2019

SELL
$39.92 - $53.86 $1.06 Million - $1.43 Million
-26,555 Reduced 40.56%
38,917 $1.88 Million
Q1 2019

May 15, 2019

SELL
$48.23 - $66.16 $1.69 Million - $2.32 Million
-35,103 Reduced 34.9%
65,472 $3.31 Million
Q4 2018

Feb 14, 2019

SELL
$55.63 - $73.24 $1.39 Million - $1.83 Million
-24,998 Reduced 19.91%
100,575 $5.96 Million
Q3 2018

Nov 14, 2018

SELL
$52.05 - $66.51 $793,970 - $1.01 Million
-15,254 Reduced 10.83%
125,573 $8.27 Million
Q2 2018

Aug 14, 2018

SELL
$48.33 - $55.64 $1.86 Million - $2.14 Million
-38,420 Reduced 21.43%
140,827 $7.11 Million
Q1 2018

May 15, 2018

SELL
$44.44 - $54.39 $2.95 Million - $3.61 Million
-66,332 Reduced 27.01%
179,247 $9.44 Million
Q4 2017

Feb 14, 2018

SELL
$37.77 - $47.75 $1.95 Million - $2.47 Million
-51,702 Reduced 17.39%
245,579 $11.4 Million
Q3 2017

Nov 14, 2017

BUY
$34.14 - $40.45 $10.1 Million - $12 Million
297,281
297,281 $12 Million

Others Institutions Holding EBS

About Emergent BioSolutions Inc.


  • Ticker EBS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,861,500
  • Market Cap $420M
  • Description
  • Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...
More about EBS
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.